$ADPT

LO FRANCIS sold $2.4M of ADPT

LO FRANCIS (Chief People Officer) sold 105,762 shares of Adaptive Biotechnologies Corp (ADPT) at $22.59 ($2.39M total) on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · LO FRANCIS
Published Jul 17, 2026, 11:23 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 17, 2026, 11:26 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ADPT
Neutral
high confidence
Mentioned
$ADPT
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADPTNeutralLow
01

Why it matters

The disclosure provides transparency on insider trading activity but does not introduce new company-specific fundamentals or guidance.

02

Market read

Traders may note insider selling activity, but the 10b5-1 designation reduces interpretive weight.

03

What to watch

Insider sales can be offset by other insider purchases or broader company catalysts not mentioned here; this filing alone does not establish directionality for future performance.

Relevance 5/10Novelty 3/10Timing: Filed 2026-07-17, reflecting a sale executed 2026-07-15.

Background

The article is an SEC Form 4 insider transaction disclosure for Adaptive Biotechnologies (ADPT).

Company-level read

Ticker impact

$ADPTNeutralHigh confidence
Context

SEC Form 4 shows Adaptive Biotechnologies insider Lo Francis sold 105,762 shares at $22.59 on 2026-07-15 under a 10b5-1 plan.

Expected impact

Likely minimal near-term price impact; any effect is more about sentiment than new company information.

Evidence & confidence

The filing is a primary-source Form 4, but it discloses no new operational, financial, or regulatory development, and explicitly notes a pre-arranged 10b5-1 plan.

Market effects

No clear read-across to biotech sector fundamentals from a single insider sale.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • Adaptive Biotechnologies Corp

    Subject of the Form 4 insider transaction disclosure.

  • Lo Francis

    Chief People Officer who sold shares.

Related articles

$ADPTMed

Adaptive Biotechnologies Corp (ADPT): Results of Operations and Financial Condition

Adaptive Biotechnologies Corp (ADPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 adpt-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results SEATTLE, Jul. 29, 2026 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnolo

$ADPTMedAI 9/10

Adaptive Biotech (ADPT) Reports 35% Revenue Growth Driven by Strong clonoSEQ Performance in Q1 2026

Adaptive Biotechnologies (NASDAQ:ADPT) reported Q1 2026 revenue of $70.9 million, up 35% year over year, driven by its MRD business, which generated 95% of revenue and rose 53%. clonoSEQ test volume increased 41% to 32,595. Net loss narrowed to $20.0 million; non-GAAP Adjusted EBITDA loss was $2.5 million. The company raised full-year 2026 MRD revenue guidance to $260–$270 million.